Drug maker Biocon has launched a biosimilar bevacizumab (referenced on Avastin) in India.
Indian drug maker Biocon announced on November 23 that it has launched a biosimilar bevacizumab (referenced on Avastin) in India. The biosimilar, which Biocon is marketing under the name Krabeva, will be used to treat patients with metastatic colorectal cancer as well as lung, kidney, cervical, ovarian, and colorectal cancer.
Arun Chandavarkar, PhD, CEO and joint managing director of Biocon, said of the launch, “With Kraveba, we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer. We believe Krabeva will be an important addition to our oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India.”
Regulatory approval for the therapy was granted on the basis of phase 3 clinical data from a study involving 146 patients with metastatic colorectal cancer. Currently, Biocon is undertaking a phase 3 trial in patients with non-small cell lung cancer at 100 sites in multiple countries, comparing its biosimilar with both US- and EU-licensed reference bevacizumab.
Notably, Biocon also announced that its bevacizumab includes a unique quality-assurance system, which it calls “QualCheck,” that will help to ensure the therapy’s quality up to the point of administration. The system comprises temperature-sensitive packaging, including thermo-chromic stickers that change color permanently if the product’s temperature rises to a level that could affect the safety, purity, or potency of the drug.
Announcement of the innovative packaging for Biocon’s bevacizumab comes at a time when many reference product sponsors and biosimilar developers are seeking ways to set their products apart from competition; after a study found that patients taking etanercept therapy preferred the auto-injector device provided with Merck’s biosimilar (Brenzys, Benpali), Amgen launched a reusable auto-injector device for its reference product (Enbrel). Amgen’s device delivers etanercept in pre-filled cartridges, and is designed to reduce injection-site pain for patients. Drug maker Takeda is also developing a novel delivery system; Takeda’s needle-free approach will allow patients to self-administer biologics using the device that will pressurize a liquid drug into a jet that pierces the skin on contact.
It remains to be seen whether Biocon’s novel packaging for its biosimilar will allow the company to claim additional market share for bevacizumab, but Biocon says that it hopes its quality-assurance system will give greater confidence to those administering the drug and will better ensure patient safety.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.